TITLE

CYTOPIA BEGINS SECOND PHASE II STUDY IN BRAIN CANCER

PUB. DATE
October 2008
SOURCE
Worldwide Biotech;Oct2008, Vol. 20 Issue 10, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the commencement of enrolment for Melbourne, Victoria-based Cytopia Limited's Phase Ib/II study of CYT997, the company's novel vascular-disrupting antineoplastic agent. The drug is aimed at patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM).
ACCESSION #
34517492

 

Related Articles

  • Antiangiogenic Strategies for Treatment of Malignant Gliomas Chi, Andrew S.; Norden, Andrew D.; Wen, Patrick Y. // Neurotherapeutics;Jul2009, Vol. 6 Issue 3, p513 

    Summary: Numerous antiangiogenic agents with diverse mechanisms of action are currently under investigation for the treatment of patients with glioblastoma (GBM), a diagnosis that continues to carry a poor prognosis despite maximal conventional therapy. Early clinical trials suggest that...

  • Brain tumor program offers new options for patients. Abrahams, John M. // Fairfield County Business Journal;2/6/2012, Vol. 48 Issue 6, p18 

    The article reports on the offer of brain tumor program to patients in Connecticut. It cites that 17,000 Americans are diagnosed with glioblastoma multiforme (GBM) which is a deadly form of brain cancer. It mentions that two national clinical trials have shown promising results which provide...

  • RTOG 0525: Examining the Effects of Dose Intensification on Survival.  // Hem/Onc Today;7/10/2012 Supplement, p5 

    The article discusses a study which determined whether dose-intensifying the postradiation temozolomide component of a chemoradiation regime improved overall survival (OS) of patients with glioblastoma.

  • Cancer Therapeutics CRC and Cytopia Ltd to collaborate on kinase target. Desjardins, Lisa; Saubern, Simon // Chemistry in Australia;Jul2008, Vol. 75 Issue 6, p36 

    The article announces that Cytopia Ltd. and Cancer Therapeutics CRC Pty. Ltd. are collaborating to develop an anti-cancer drug to treat metastatic cancers. Cytopia has extended its proprietary technology to Cancer Therapeutics to study kinase enzyme target to treat metastatic cancers. Cancer...

  • Taking on a Monster. Egan, Mary Ellen // Forbes Global;11/15/2004, Vol. 7 Issue 20, p64 

    Offers a look on two prospective drugs for brain cancer, IL-13 and Transmid, that are giving patients a new lease on life as of 20014. Background on the case of David Herbert, a former pilot diagnosed with glioblastoma multiforme; Makers of IL-13 and Transmid; Number of U.S. citizens diagnosed...

  • Inhibition of Elongation Factor-2 Kinase Augments the Antitumor Activity of Temozolomide against Glioma. Liu, Xiao-yuan; Zhang, Li; Wu, JianPing; Zhou, Lei; Ren, Yi-Jie; Yang, Wei-Qiong; Ming, Zi-Jun; Chen, Bo; Wang, Jianrong; Zhang, Yi; Yang, Jin-Ming // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Background:Glioblastoma multiforme (GBM), the most common form of brain cancer with an average survival of less than 12 months, is a highly aggressive and fatal disease characterized by survival of glioma cells following initial treatment, invasion through the brain parenchyma and destruction of...

  • In Vivo/Ex Vivo and In Situ Assays Used in Cancer Research: A Brief Review. Teicher, Beverly A. // Toxicologic Pathology;2009, Vol. 37 Issue 1, p13 

    Predicting whether a potential new anticancer agent will have a positive therapeutic index in patients remains a challenge. This brief review provides examples of preclinical in vivo/ex vivo and in situ assays used to assess the therapeutic potential of experimental anticancer therapeutics....

  • Design of New Oxazaphosphorine Anticancer Drugs. Jun Liang; Min Huang; Wei Duan; Xue-Qing Yu; Shufeng Zhou // Current Pharmaceutical Design;Mar2007, Vol. 13 Issue 9, p963 

    The oxazaphosphorines including cyclophosphamide (CPA, Cytoxan, or Neosar), ifosfamide (IFO, Ifex) and trofosfamide (Ixoten) represent an important group of therapeutic agents due to their substantial antitumor and immunomodulating activity. However, several intrinsic limitations have been...

  • Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Robins, H. Ian; Won, M.; Seiferheld, Wendy F.; Schultz, Christopher J.; Choucair, Ali K.; Brachman, David G.; Demas, William F.; Mehta, Minesh P. // Neuro-Oncology;Jan2006, Vol. 8 Issue 1, p47 

    Preclinical studies support the concept that inhibition of protein kinase C (PKC) by tamoxifen (TAM) should provide both antineoplastic effects and radiosensitization. High-dose TAM (80 mg/m² p.o. daily in divided doses) was given with and after conventional radiotherapy (XRT) to inhibit...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics